Clinical Trials | June 02, 2026
Eli Lilly drug slashes lung cancer recurrence risk by 83% in landmark phase 3 trial
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
The approval is supported by results from the Phase 3 SWOG 1826 trial
While overall survival data remain immature, the results pointed to a favourable trend.
Initiatives at Churchgate Station and Mahindra & Mahindra focus on early detection, public education, and tobacco-related cancer prevention
While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
Increasing syphilis cases, stronger STI surveillance initiatives, and growing emphasis on early diagnosis are expected to support sustained demand
The approval marks a major milestone in the global fight against antimicrobial resistance
The results confirm the study’s primary endpoint of objective response rate and now deliver a striking signal in progression-free survival
Subscribe To Our Newsletter & Stay Updated
